Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence

Giancarlo Ripabelli; Angelo Salzo; Manuela Tamburro

doi:10.1080/21645515.2023.2168947

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence

Hum Vaccin Immunother. 2023 Dec 31;19(1):2168947. doi: 10.1080/21645515.2023.2168947. Epub 2023 Jan 19.

Authors

Giancarlo Ripabelli¹, Angelo Salzo², Manuela Tamburro¹

Affiliations

¹ Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.
² Local Health Agency of Molise Region, Campobasso, Italy.

Abstract

Dear Editor, We would like to reply to "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11years: Correspondence" regarding our article entitled "Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNTech) vaccine in children aged 5-11years: Results from an active pharmacovigilance study in central Italy."

Publication types

Letter
Comment

MeSH terms

BNT162 Vaccine
COVID-19* / prevention & control
Child
Humans
Italy / epidemiology
RNA, Messenger
Vaccines*

Substances

BNT162 Vaccine
Vaccines
RNA, Messenger

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.